This report was first published by Endpoints News. To see the original version, click here
Eli Lilly may not have discovered orexins, but the pharma’s latest acquisition marks increasing momentum for a drug class that’s maturing after years of fine-tuning.
The big question on the minds of Wall Street is whether orexins’ potential is fully known.
您已阅读9%（345字），剩余91%（3370字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。